OSTEOPONTIN IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS AS A PREDICTOR OF CARDIOVASCULAR EVENTS
- 作者: Suvorova N.A.1,2, Gordeev I.G.3, Luchinkina E.E.3
-
隶属关系:
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
- O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (on the basis of O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow)
- 期: 卷 8, 编号 9 (2022)
- 页面: 53-59
- 栏目: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/276835
- DOI: https://doi.org/10.18565/therapy.2022.9.53-58
- ID: 276835
如何引用文章
详细
全文:
作者简介
Natalya Suvorova
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow
Email: natalia-suvorova@inbox.ru
assistant at the Department of hospital therapy named after Academician P.E. Lukomsky of the Faculty of general medicine; general practitioner 111539, Moscow, 23/4 Veshnyakovskaya Str
Ivan Gordeev
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (on the basis of O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow)Dr. med. habil., professor; head of the Department of hospital therapy named after Academician P.E. Lukomsky of the Faculty of general medicine 111539, Moscow, 23/4 Veshnyakovskaya Str
Elena Luchinkina
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (on the basis of O.M. Filatov City Clinical Hospital No. 15 of the Department of Healthcare of Moscow)PhD in Medicine, associate professor of the Department of hospital therapy named after Academician P.E. Lukomsky of the Faculty of general medicine 111539, Moscow, 23/4 Veshnyakovskaya Str
参考
- Halpin D.M.G., Celli B.R., Criner G.J. The GOLD Summit on chronic obstructive pulmonary disease in lowand middle-income countries.Int J Tuberc Lung Dis. 2019; 23(11): 1131-41. https://dx.doi.org/10.5588/ijtld.19.0397.www.therapy-journal.ru www.rnmot.ru
- Rabe K.F., Hurst J.R., Suissa S. Cardiovascular disease and COPD: Dangerous liaisons? Eur Respir Rev. 2018; 27(149): 180057. https://dx.doi.org/10.1183/16000617.0057-2018.
- Chen W., Thomas J., Sadatsafavi M., FitzGerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Lancet Respir Med. 2015; 3(8): 631-39. https://dx.doi.org/10.1016/S2213-2600d5)00241-6.
- Игнатова ГЛ., Антонов В.Н. Прогностические индексы и маркеры системного воспаления у пациентов с ХОБЛ и ИБС. Медицинский совет. 2017; 4: 81-85. [Ignatova G.L., Antonov V.N. Prognostic indices and markers of systemic inflammation in patients with COPD and CaD. Meditsinskiy sovet = Medical Council. 2017; 4: 81-85 (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2017-4-81-85. EDN: YPTJGL.
- Гайнитдинова В.В., Авдеев С.Н., Неклюдова Г.В. с соавт. Влияние сопутствующих сердечно-сосудистых заболеваний на течение и прогноз хронической обструктивной болезни легких. Пульмонология. 2019; 29(1): 35-42. https://dx.doi.org/10.18093/0869-0189-2019-29-1-19-34. EDN: QKZVAQ.
- Kraen M., Frantz S., Nihlen U. et al. Matrix metalloproteinases in COPD and atherosclerosis with emphasis on the effects of smoking. PLoS One. 2019; 14(2): e0211987. https://dx.doi.org/10.1371/journal.pone.0211987.
- Hawkins N.M., Khosla A., Virani S.A. et al. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med. 2017; 17(1): 11. https://dx.doi.org/10.1186/s12890-016-0345-7.
- Miller J., Edwards L.D., Agusti A. et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013; 107(9): 1376-84. https://dx.doi.org/10.1016/j.rmed.2013.05.001.
- Zhu Z., He Y., Shi M. et al. Plasma osteopontin levels and adverse clinical outcomes after ischemic stroke. Atherosclerosis. 2021; 332: 33-40. https://dx.doi.org/10.1016/j.atherosclerosis.2021.07.010.
- Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014; 236(2): 327-37. https://dx.doi.org/10.1016/j.atherosclerosis.2014.07.004.
- Abdalrhim A.D., Marroush T.S., Austin E.E. et al. Plasma osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. PLoS One. 2016; 11(6): e0156965. https://dx.doi.org/10.1371/journal.pone.0156965.
- Lee S.J., Kim S.H., Kim W. et al. Increased plasma osteopontin in frequent exacerbator and acute exacerbation of COPD. Clin Respir J. 2014; 8(3): 305-11. https://dx.doi.org/10.1111/crj.12072.
- Papaporfyriou A., Loukides S., Kostikas K. et al. Increased levels of osteopontin in sputum supernatant in patients with COPD. Chest. 2014; 146(4): 951-58. https://dx.doi.org/10.1378/chest.13-2440.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2021. URL: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf (date of access - 01.11.2022).
- Westerik J.A., Metting E.I., van Boven J.F. et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017; 18(1): 31. https://dx.doi.org/10.1186/s12931-017-0512-2.
- Keene J.D., Jacobson S., Kechris K. et al; COPDGene and SPIROMICS Investigators. Biomarkers predictive of exacerbations in the SPIROMIcS and COPDGene cohorts. Am J Respir Crit Care Med. 2017; 195(4): 473-81. https://dx.doi.org/10.1164/rccm.201607-1330OC.